论文部分内容阅读
目的观察125I粒子联合胶体32P组织间介入治疗中晚期非小细胞肺癌的近期疗效。方法选取中晚期非小细胞肺癌患者40例,应用治疗计划系统(Treatment Planning System,TPS)制定计划,在计算机X射线断层扫描(computed tomography,CT)引导下实施125I粒子植入治疗,胶体32P组织间介入补充治疗,术后随访3至6个月。结果 40例患者中术后第3、6个月治疗有效率(包括完全消退和部分消退,CR+PR)分别为77.5%、82.5%;血清中CYFRA21-1、CEA等肿瘤标志物与植入前比较差异有统计学意义(P<0.01);肿瘤疗效评价分类不同,其相应肿瘤标志物浓度差异有统计学意义。结论 125I粒子联合胶体32P组织间介入治疗是一种有效治疗中晚期非小细胞肺癌的方法 ,值得临床推广。
Objective To observe the short-term effect of intervening 125I particles with colloidal 32P on advanced non-small cell lung cancer. Methods Totally 40 patients with advanced non-small cell lung cancer (NSCLC) were enrolled in this study. TPS was used to make plans. Under the guidance of computed tomography (CT), 125I seeds were implanted. Colloidal 32P tissue Between the interventional therapy, followed up for 3 to 6 months. Results The effective rate (including complete remission and partial remission, CR + PR) in the 40 patients at 3 and 6 months postoperatively were 77.5% and 82.5% respectively. The serum CYFRA21-1, CEA and other tumor markers and implantation The difference was statistically significant before (P <0.01). There were significant differences in the evaluation of tumor efficacy between the corresponding tumor marker concentrations. Conclusion Interventional treatment with 125I particles and colloidal 32P tissue is an effective method for the treatment of advanced non-small cell lung cancer, and is worthy of clinical promotion.